androgen deprivation therapy

  • June 14, 2022  

    How an Expert Would Manage His Own Advanced Prostate Cancer

    With: Marc B. Garnick, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »

  • April 20, 2022  

    Triplet Combination Improves Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer Bookmark

    George Lundberg, MD

    Metastatic carcinoma of the prostate is fatal, but a 3-drug combination treatment can prolong life substantially, according to new clinical trial results outlined by The ASCO Post.

    .

  • August 15, 2020  

    New Focus on ADT in Prostate Cancer Guideline Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Hormone therapy has been a mainstay in the treatment of metastatic prostate cancer. But, until now, guidelines have been short on detail. This news story outlines 38 approved additions to guidelines.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 22, 2018  

    The Link Between Apalutamide and QOL in Non-Metastatic CRPC Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “Adding apalutamide to androgen deprivation therapy (ADT) does not appear to harm health-related quality of life (HRQOL) in men with nonmetastatic castration-resistant prostate cancer (CRPC), according to new research published in Lancet Oncology.

    “Previous research has showed that men in this patient population who received apalutamide had longer metastasis-free survival and a longer time to symptomatic progression compared with those who received placebo. This new study found that adding apalutamide still preserves HRQOL. Specifically, the group mean patient-reported outcome scores over time demonstrated HRQOL was maintained from baseline (initiation of apalutamide), and it was similar over time among men receiving apalutamide versus placebo.”

    Go to full article published by Cancer Network on Oct 9, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • June 18, 2015  

    ASCO 2015: Notable Reports on Prostate Cancer Treatment

    Emma Shtivelman, PhD

    This year’s American Society of Clinical Oncology (ASCO) annual meeting was short on any truly exciting developments in prostate cancer treatment. In stark contrast to other cancers, such as lung, breast, kidney, and melanoma, there were no reports of note on targeted and immunotherapies in prostate cancer. The two presentations summarized here offered new strategies in chemotherapy.

  • February 17, 2015  

    Now BATting: A New Treatment Approach That Uses Testosterone First, Then ADT

    Emma Shtivelman, PhD

    Androgen deprivation therapy (ADT) has long been a mainstay in the management of prostate cancer. Indeed, the vast majority of prostate cancers depend on androgens (hormones like testosterone) for their growth. Lowering testosterone levels with ADT is a reasonable approach. But it comes with two sets of problems.